Effect and safety of tirofiban in acute coronary syndrome patients with no reflow after intevention procedure

VernacularTitle:替罗非班治疗急性冠脉综合征介入术后无复流的疗效观察
Author: Zongyun HE ; Yanxian WU ; Yunzhao HU
Publication Type:Journal Article
Keywords: Tirofiban; Coronary disease
From: Chinese Journal of Primary Medicine and Pharmacy 2009;16(3):475-477
CountryChina
Language:Chinese
Abstract: Objective To observe the clinical effect and safety of platdet GP Ⅱb/Ⅲa receptor antagonist firofiban on acute coronary syndrome(ACS)patients with nO reflow after intevention procedure.Methods 48 ACS patients with no reflow were randomly divided into tirofiban group(n=26)and control group(n=22),the tirofiban group received intravenous tirofiban for 48-36homs,control group received nitroglycerin and urokinase.The rate of the TIMI grade offorward flow and the primary end pints(death,persistent myocardial isehemic and new onset myocardial infarction)and adverse reactions of drags were observed Resalts Tirofiban improved target vessel TIMI flow significantly than control groug(73.8%vs 18.2%,P＜0.01),the rate of the main end point events significantly decreased(15.4%vs 63.6%,P＜0.05),the bleeding complications was similar between two groups,no severe bleeding events occurred.Condusion Tirofiban is effecfive and safe in treating ACS patients with no reflow.